drugset / Trial / NCT03413319
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
Timeline
- Start
- 2018-04-17
- Primary completion
- 2019-11-20
- Completion
- 2019-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tilavonemab | Monoclonal antibody | — | Intravenous |